NO2 inhalation promotes Alzheimer's disease-like progression: Cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yan, Wei ^a   Yun, Yang ^a   Ku, Tingting ^a   Li, Guangke ^a   Sang, Nan ^a  

^a SHANXI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL; ACYLGLYCEROL LIPASE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; CYCLOOXYGENASE 2; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE; NITROGEN DIOXIDE; PEPTIDE FRAGMENT; PROSTAGLANDIN E2; PTGS2 PROTEIN, MOUSE;

ADVERSE EFFECTS; AIR POLLUTION; ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; COGNITIVE DEFECT; DRUG EFFECTS; LIQUID CHROMATOGRAPHY; METABOLISM; MOUSE; SPATIAL LEARNING; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE;

AIR POLLUTION; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; CHROMATOGRAPHY, LIQUID; COGNITIVE DYSFUNCTION; CYCLOOXYGENASE 2; DINOPROSTONE; ENDOCANNABINOIDS; GLYCERIDES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOACYLGLYCEROL LIPASES; NITROGEN DIOXIDE; PEPTIDE FRAGMENTS; SPATIAL LEARNING; TANDEM MASS SPECTROMETRY;

EID: 84959527717     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22429     Document Type: Article

References (49)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 11, 332-384.
2. Martin, P. et al. World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer's Disease International (ADI), London (2015).
3. Michael, W. et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 9, e111-e194 (2013).
4. Moreno, G. I., Lisbell, D. E., Elisabeth, S. M. & Soto C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nat. Commun. 4, 1495 (2013).
5. Moulton, P. V. & Yang, W. Air pollution, oxidative stress, and Alzheimer's disease. J. Environ. Public. Health. 2012, 1-9 (2012).
6. Calderón-Garcidueñas, L. et al. Environmental Air Pollution and Brain Damage. Toxicol. Pathol. 30, 373-389 (2002).
7. Calderón-Garciduenãs, L. et al. Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution. Toxicol. Pathol. 32, 650-658 (2004).
8. Block, M. L. & Calderón-Garcidueñas, L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends. Neurosci. 32, 506-516 (2009).
9. Weuve, J. et al. Exposure to particulate air pollution and cognitive decline in older women. Arch. Intern. Med. 172, 219-227(2012).
10. 2/NOx ratio from lean-burn natural gas engines. J. Air. Waste. Manag. Assoc. 60, 867-874 (2010).
11. Department of Health, Committee on the Medical Aspects of Air Pollutants. Asthma and Outdoor Pollution. HMSO, London (1995).
12. Pathmanathan, S. et al. Repeated daily exposure to 2 ppm nitrogen dioxide upregulates the expression of IL-5, IL-10, IL-13, and ICAM-1 in the bronchial epithelium of healthy human airways. Occup. Environ. Med. 60, 892-896 (2003).
13. Morales, E. et al. Association of early-life exposure to household gas appliances and indoor nitrogen dioxide with cognition and attention behavior in preschoolers. Am. J. Epidemiol. 169, 1327-1336 (2009).
14. Wang, S. et al. Association of traffic-related air pollution with children's neurobehavioral functions in Quanzhou, China. Environ. Health. Perspect. 117, 1612-1618 (2009).
15. Gatto, N. M. et al. Components of air pollution and cognitive function in middle-aged and older adults in Los Angeles. Neurotoxicology. 40, 1-7 (2014).
16. Liu, P. et al. A survey of the psychological state and neurobehavioral function of traffic policemen [in Chinese]. China. Occup. Med. 27, 7-9 (2001).
17. Wang, Y. S., Zhang, H. Y. & Chen, W. J. Investigation of nerve behavior function of drivers and busmen [in Chinese]. Anhui.J. Prev. Med. 8, 315-353 (2002).
18. Grundman, M. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch. Neurol. 61, 59-66 (2004).
19. Maioli, F. et al. Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. Arch. Gerontol. Geriatr. 44, 233-241 (2007).
20. Pujadas, L. et al. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. Nat. Commun. 5, 3443 (2014).
21. Garcia-Alloza, M. et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516-524 (2006).
22. Yang, H. & Chen, C. Cyclooxygenase-2 in synaptic signaling. Curr. Pharm. Des. 14, 1443-1451 (2008).
23. Lima, I. V. et al. Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators. Inflamm. 2012, 1-13 (2012).
24. Rao, J. S., Rapoport, S. I. & Kim, H. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain. Transl. Psychiatry. 1, e31 (2011).
25. Dajani, E. Z. & Islam, K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J. Physiol. Pharmacol. 2, 117-133 (2008).
26. Xu, J. & Chen, C. Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist. 21, 152-168 (2015).
27. Nomura, D. K. et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 334, 809-813 (2011).
28. Chen, R. et al. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell. Rep. 2, 1329-1339 (2012).
29. Piro, J. R. et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell. Rep. 1, 617-623 (2012).
30. Zhang, J. & Chen, C. Endocannabinoid 2-Arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283, 22601-22611 (2008).
31. Hoshino, T. et al. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J. Biol. Chem. 282, 32676-32688 (2007).
32. 2 (air pollution and air quality) satellite measurements over other regions in the world.
33. Alzheimer's Disease International, Alzheimer's Australia. Dementia in the Asia Pacific Region. Alzheimer's Disease International (ADI), London (2014).
34. Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet. Neurol. 12, 207-216 (2013).
35. Calderón-Garcidueñas, L. et al. Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alphasynuclein in children and young adults. Toxicol Pathol. 36, 289-310 (2008).
36. 2) exposure enhances airway inflammation via modulatingTh1/Th2 differentiation and activating JAK-STAT pathway. Chemosphere. 120, 722-728 (2015).
37. 2 inhalation exposure. Chemosphere. 82, 1589-1596 (2011).
38. Yan, W., Ji, X., Shi, J., Li, G. & Sang, N. Acute nitrogen dioxide inhalation induces mitochondrial dysfunction in rat brain. Environ. Res. 138, 416-424 (2015).
39. Sang, N. & Chen, C. Lipid signaling and synaptic plasticity. Neuroscientist. 12, 425-434 (2006).
40. Combrinck, M. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 77, 85-88 (2006).
41. Zhen, G. et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. Neurobiol. Aging. 33, 2215-2219 (2012).
42. Tonne, C., Elbaz, A., Beevers, S. & Singh-Manoux, A. Traffic-related air pollution in relation to cognitive function in older adults. Epidemiol. 25, 674-681 (2014).
43. Campbell, A. et al. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology. 26, 133-140 (2005).
44. Vlad, S. C., Miller, D. R., Kowall, N. W. & Felson, D. T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 70, 1672-1677 (2008).
45. Richard, O. et al. The vascular effects of COX-2 selective inhibitors. Aust. Prescr. 27, 142-145 (2004).
46. Alger, B. E. Endocannabinoid signaling in neural plasticity. Curr. Top. Behav. Neurosci. 1, 1141-1172 (2009).
47. Chen, X., Zhang, J. & Chen, C. Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience. 178, 159-168 (2011).
48. Du, H., Chen, X., Zhang, J. & Chen, C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br. J. Pharmacol. 163, 1533-1549 (2011).
49. Querfurth, H. W. & LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med. 362, 329-344 (2010).